$54.99
This item has been third-party tested by accredited U.S. laboratories and confirmed to meet a minimum purity of 98% through rigorous verification standards.
$54.99
Synthetic pentapeptide growth hormone secretagogue (selective GHS-R agonist) — lyophilized powder. Supplied by Research Chemical exclusively for laboratory research use.
Lyophilized powder, sterile glass vial.
Independently analyzed by an accredited third-party lab.
5-amino-acid GHS-R ligand, confirmed by mass spectrometry.
Supplied exclusively for laboratory investigation.
| Compound Class | Synthetic Pentapeptide (Selective Growth Hormone Secretagogue / GHS-R Agonist) |
|---|---|
| Form | Lyophilized powder, sterile glass vial |
| Amount per Vial | 5 mg |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| CAS Number | 170851-70-4 |
| Chemical Formula | C38H49N9O5 |
| Molar Mass | 711.9 g/mol |
| Synonyms | Ipamorelin, NNC 26-0161 |
| Verified Purity | Batch-tested to 98% (HPLC) |
For laboratory research use only. Not for human or animal consumption.
Each peptide batch is analyzed by an accredited third-party laboratory before it ships.

Most recent batch certificate of analysis, issued by MZ Biolabs. Click to view full size on the certificates page.
Every batch sold by Research Chemical is independently analyzed before it ships.
This product is an investigational compound and is not a drug, food, dietary supplement, or cosmetic. It is not approved for human or animal use, and it is unlawful to market it for that purpose.
Ipamorelin is a growth hormone secretagogue, prohibited by the World Anti-Doping Agency (WADA) at all times under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics).
Research Chemical makes no representations regarding the safety or effects of this compound in humans or animals.
Research Chemical is a chemical supplier, not a medical provider. We do not condone or encourage consumer use of research compounds.
Research use only. All products sold by Research Chemical are intended exclusively for laboratory research and development. They are not for human or animal consumption. These statements have not been evaluated by the U.S. Food and Drug Administration, and these products are not intended to diagnose, treat, cure, or prevent any disease.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Research Chemical products are third-party tested by MZ Biolabs, an independent laboratory based in Arizona. Each batch is analyzed to ensure accuracy, purity, and that all specifications are met.

By purchasing from ResearchChemical.com, you acknowledge that you are acquiring research chemicals intended solely for scientific investigation.
Ipamorelin is:
The information provided on this page is for educational and informational purposes only and should not be interpreted as medical advice. ResearchChemical.com assumes no liability for misuse, improper handling, or use outside of controlled research environments. It is the purchaser’s responsibility to ensure compliance with all applicable laws and regulations.
1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective GH secretagogue. European Journal of Endocrinology. 1998 Oct;139(5):552-61. doi: 10.1530/eje.0.1390552.
2. Johansen, P. B., Nowak, J., Skjærbæk, C., Flyvbjerg, A., Andreassen, T. T., Wilken, M., & Ørskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106-113.
3. Vahl, N., Juul, A., Jørgensen, J. O., Ørskov, H., Skakkebæk, N. E., & Christiansen, J. S. (2000). Continuation of GH replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study. The Journal of Clinical Endocrinology & Metabolism, 85(5), 1874-1881.
4. Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., … & Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of GH secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 9(Suppl 2), S149.
5. Horvath, T. L., Castañeda, T., Tang-Christensen, M., Pagotto, U., & Tschop, M. H. (2003). Ghrelin as a potential anti-obesity target. Current Pharmaceutical Design, 9(17), 1383-1395.
6. Sjögren, K., Jansson, J. O., Isaksson, O. G., & Ohlsson, C. (2002). A model for tissue-specific inducible insulin-like growth factor-I (IGF-I) inactivation to determine the physiological role of liver-derived IGF-I. Endocrine, 19, 249-256.
7. D’Agostino, P. IGF-1 LR3: The rapid-acting GH alternative.
8. Ishida, J., Saitoh, M., Ebner, N., Springer, J., Anker, S. D., & von Haehling, S. (2020). Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications, 3(1), 25-37.
9. Adeghate, E., & Ponery, A. S. (2004). Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuroendocrinology Letters, 25(6), 403-406.
10. Andersen, N. B., Malmlöf, K., Johansen, P. B., Andreassen, T. T., Ørtoft, G., & Oxlund, H. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Hormone & IGF Research, 11(5), 266-272.
Please note that the above references provide evidence for the potential benefits of Ipamorelin Peptide as stated in the product description. For more in-depth information, refer to these scholarly works.




Join our insider list for the latest research insights, product releases, and special offers—delivered straight to your inbox.